Skip navigation
Universidade Federal da Bahia |
Repositório Institucional da UFBA
Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/17673
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorBoy, Raquel-
dc.contributor.authorSchwartz, Ida Vanessa Doederlein-
dc.contributor.authorKrug, Bárbara C.-
dc.contributor.authorSilva, Luiz C. Santana da-
dc.contributor.authorSteiner, Carlos Eduardo-
dc.contributor.authorAcosta, Angelina Xavier-
dc.contributor.authorRibeiro, Erlane M.-
dc.contributor.authorGalera, Marcial F.-
dc.contributor.authorLeivas, Paulo G. C.-
dc.contributor.authorBraz, Marlene-
dc.creatorBoy, Raquel-
dc.creatorSchwartz, Ida Vanessa Doederlein-
dc.creatorKrug, Bárbara C.-
dc.creatorSilva, Luiz C. Santana da-
dc.creatorSteiner, Carlos Eduardo-
dc.creatorAcosta, Angelina Xavier-
dc.creatorRibeiro, Erlane M.-
dc.creatorGalera, Marcial F.-
dc.creatorLeivas, Paulo G. C.-
dc.creatorBraz, Marlene-
dc.date.accessioned2015-05-11T16:31:38Z-
dc.date.issued2011-
dc.identifier.issn0306-6800-
dc.identifier.urihttp://repositorio.ufba.br/ri/handle/ri/17673-
dc.descriptionTexto completo: acesso restrito. p. 233-239pt_BR
dc.description.abstractBackground/Aims Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disorder treated with bone marrow transplantation or enzyme replacement therapy with laronidase, a high-cost orphan drug. Laronidase was approved by the US Food and Drug Administration and the European Medicines Agency in 2003 and by the Brazilian National Health Surveillance Agency in 2005. Many Brazilian MPS I patients have been receiving laronidase despite the absence of a governmental policy regulating access to the drug. Epidemiological and treatment data concerning MPS I are scarce. This study aims to present a demographic profile of Brazilian patients with MPS I, describe the routes of access to laronidase in Brazil, and discuss associated ethical issues relating to public funding of orphan drugs. Methods In this cross-sectional observational study, data were collected nationwide between January and September 2008 from physicians, public institutions and non-governmental organisations involved with diagnosis and treatment of MPS I, using two data collection instruments specifically designed for this purpose. Results The minimum prevalence of MPS I in Brazil was estimated at 1/2 700 000. Most patients (69.8%) were younger than 15 years; 60 (88.2%) received laronidase. The most common route of access to the drug was through lawsuits (86.6%). Conclusions In Brazil, MPS I is predominantly a paediatric illness. Even though the cost of laronidase treatment is not officially covered by the Brazilian government, most MPS I patients receive the drug, usually through litigation. This gives rise to major ethical conflicts concerning drug access in a low-resource context. The Brazilian health policy framework lacks evidence-based clinical protocols for the distribution of orphan drugs.pt_BR
dc.language.isoenpt_BR
dc.rightsAcesso Abertopt_BR
dc.sourcehttp://dx.doi.org/ 10.1136/jme.2010.037150pt_BR
dc.subjectMucopolysaccharidosispt_BR
dc.subjectMucopolysaccharidosis Ipt_BR
dc.subjectLaronidasept_BR
dc.titleEthical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type Ipt_BR
dc.title.alternativeJournal of Medical Ethicspt_BR
dc.typeArtigo de Periódicopt_BR
dc.identifier.numberv. 37, n. 4pt_BR
dc.embargo.liftdate10000-01-01-
Aparece nas coleções:Artigo Publicado em Periódico (Faculdade de Medicina)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Angelina X Acosta.pdf256,13 kBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.